Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00708799 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Macrolide Immunomodulation in Severe Sepsis.
A Phase 2 study, sponsored by VA Office of Research and Development.
- Terminated
- Registry status
- Phase 2
- Development phase
- 100
- Enrollment target
NCT00708799: Clinical Trial Phase 2 study, sponsored by VA Office of Research and Development.
NCT00708799 is a Phase 2 study that was terminated before completion, run by VA Office of Research and Development. The registered enrollment target is 100 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00708799, a Phase 2 study, was terminated before completion, sponsored by VA Office of Research and Development.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 100 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether macrolide treatment of patients with severe sepsis has an advantageous immunomodulatory and clinical effect compared to severe septic patients without macrolide therapy. Our main hypothesis is macrolide use in addition to standard therapy in severe septic patients has an advantageous immunomodulatory and clinical effect compared to patients with severe sepsis not treated with a macrolide.
Interventions
- OTHER Azithromycin on admission - not enrolled in the RCT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2007-11 |
| Est. Completion | 2013-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00708799
The ClinicalTrials.gov registry entry for NCT00708799 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azithromycin on admission - not enrolled in the RCT is the first listed.
NCT00708799 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00708799 about?
NCT00708799 is a clinical study titled "Efficacy of Macrolide Immunomodulation in Severe Sepsis.". The purpose of this study is to determine whether macrolide treatment of patients with severe sepsis has an advantageous immunomodulatory and clinical effect compared to severe septic patients without macrolide therapy. Our main hypothesis is macrolide use in addition to standard therapy in severe s...
What is the current status of trial NCT00708799?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 100 participants. The study started on 2007-11. Estimated completion is 2013-11.
What interventions are being tested in trial NCT00708799?
The interventions under investigation include: Azithromycin on admission - not enrolled in the RCT (OTHER).
Who is sponsoring clinical trial NCT00708799?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.